The Role of the Microbiome in Lichen Sclerosus: Pathophysiological Insights and Therapeutic Implications - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Microbiome's Influence on Lichen Sclerosus: Insights into Pathophysiology and Treatment Options

  • By

  • Marta Kasprowicz-Furmańczyk

  • Witold Chmielnicki

  • Natalia Zdanowska

  • Agnieszka Owczarczyk-Saczonek

  • September 19, 2026

Share

  • 1

    Lichen sclerosus (LS) is a chronic inflammatory and fibrotic dermatosis, traditionally classified as an autoimmune condition.

  • 2

    Microbiome dysbiosis may contribute to LS pathogenesis and is associated with an increased risk of squamous cell carcinoma.

  • 3

    Studies show heterogeneous microbiome alterations in LS across various anatomical sites, influenced by methodological variability.

  • 4

    Dysbiosis may drive immune dysregulation and chronic inflammation, potentially through mechanisms involving mucosa-associated invariant T cells.

  • 5

    Further longitudinal and interventional research is needed to establish causality and clinical applicability of microbiome findings in LS.

Original Source(s)

The Role of the Microbiome in Lichen Sclerosus: Pathophysiological Insights and Therapeutic Implications

  • by Marta Kasprowicz-Furmańczyk, Witold Chmielnicki, Natalia Zdanowska, Agnieszka Owczarczyk-Saczonek

  • September 19, 2026

Related Content

Cellulitis-like cutaneous cryptococcosis revealing disseminated infection in a kidney transplant recipient: a case report and systematic review

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

Do antihistamines help atopic dermatitis?

First-generation H1 antihistamines likely increase cognitive impairment, with cognitive effects differing among second-generation antihistamines.